Frank Karbe insider trades: Phathom Pharmaceuticals (PHAT) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Frank reports to the SEC
and 1 more company
Open-market buys and sales
22 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 13, 2024 | PHAT | ↑ Buy | 12,500 | $7.93 | $99K | Direct | Dec 16, 2024 (3d) |
| Jul 27, 2023 | BTTX | ↑ Buy | 137,005 | $0.73 | $100K | Direct | Jul 31, 2023 (4d) |
| Apr 10, 2023 | BTTX | ↑ Buy | 242,424 | $0.82 | $200K | Direct | Apr 12, 2023 (2d) |
| Sep 15, 2022 | BTTX | ↑ Buy | 50,000 | $2.09 | $105K | Direct | Sep 15, 2022 (0d) |
| Jul 7, 2021 | MYOV | ↓ Sell | 3,232 | $21.75 | $70K | Direct | Jul 9, 2021 (2d) |
| Apr 6, 2021 | MYOV | ↓ Sell | 11,080 | $18.63 | $206K | Direct | Apr 8, 2021 (2d) |
| Feb 16, 2021 | MYOV | ↓ Sell10b5-1 | 750 | $21.40 | $16K | Direct | Feb 18, 2021 (2d) |
| Jan 28, 2021 | MYOV | ↓ Sell10b5-1 | 300 | $24.00 | $7K | Direct | Feb 1, 2021 (4d) |
| Jan 15, 2021 | MYOV | ↓ Sell10b5-1 | 750 | $21.50 | $16K | Direct | Jan 20, 2021 (5d) |
| Dec 28, 2020 | MYOV | ↓ Sell10b5-1 | 11,800 | $30.00 | $354K | Direct | Dec 30, 2020 (2d) |
| Dec 15, 2020 | MYOV | ↓ Sell10b5-1 | 670 | $24.45 | $16K | Direct | Dec 17, 2020 (2d) |
| Dec 15, 2020 | MYOV | ↓ Sell10b5-1 | 380 | $23.63 | $9K | Direct | Dec 17, 2020 (2d) |
| Nov 30, 2020 | MYOV | ↓ Sell10b5-1 | 1,500 | $24.00 | $36K | Direct | Dec 2, 2020 (2d) |
| Nov 17, 2020 | MYOV | ↓ Sell10b5-1 | 750 | $20.00 | $15K | Direct | Nov 19, 2020 (2d) |
| Nov 13, 2020 | MYOV | ↓ Sell10b5-1 | 750 | $20.00 | $15K | Direct | Nov 17, 2020 (4d) |
| Sep 15, 2020 | MYOV | ↓ Sell10b5-1 | 750 | $21.73 | $16K | Direct | Sep 17, 2020 (2d) |
| Aug 31, 2020 | MYOV | ↓ Sell10b5-1 | 24,800 | $20.02 | $496K | Direct | Sep 1, 2020 (1d) |
| Aug 19, 2020 | MYOV | ↓ Sell10b5-1 | 700 | $20.00 | $14K | Direct | Aug 21, 2020 (2d) |
| Dec 30, 2019 | MYOV | ↓ Sell | 19,701 | $15.55 | $306K | Direct | Dec 30, 2019 (0d) |
| Jun 11, 2019 | MYOV | ↑ Buy | 8,000 | $9.10 | $73K | Direct | Jun 11, 2019 (0d) |
| Aug 24, 2010 | EXEL | ↑ Buy | 16,500 | $2.98 | $49K | Direct | Aug 25, 2010 (1d) |
| Oct 31, 2008 | EXEL | ↑ Buy | 17,500 | $3.28 | $57K | Direct | Oct 31, 2008 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Frank Karbe's insider trades
Frank Karbe is an insider at Phathom Pharmaceuticals (PHAT). Since Oct 31, 2008, Frank has reported 7 open-market purchases worth $683K and 15 sales worth $1.6M on SEC Form 4. There have been no open-market trades in the last 12 months.
12 sales (63% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (32 filings), option exercises (24 filings), shares withheld for taxes (10 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PHAT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.